Journal: International Journal of Molecular Sciences
Article Title: In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model
doi: 10.3390/ijms27010064
Figure Lengend Snippet: Assessment of Nintedanib target engagement. Nintedanib (light blue columns) did not modify lung levels of PDGF ( A ), which was unaffected by BLM, while significantly attenuated FGF2 lung levels ( B ) were enhanced by BLM. In contrast, lung ( C ) and plasma ( D ) VEGF levels were significantly increased by Nintedanib treatment relative to both untreated (control) and BLM treated groups. Panel ( E , F ) illustrates the rise in VEGF levels in lung and plasma, respectively, observed at different time points following Nintedanib treatment in BLM-free animals. Statistical analysis was performed with the one-way ANOVA followed by Dunnett’s test. A p -value < 0.05 was considered statistically significant. * p < 0.05, ** p < 0.01 when compared to the control group (cream columns, Panels A – D ) or time points 0 (Panels E , F ). # p < 0.05 when compared to BLM + Vehicle group (teal blue columns, Panels A – D ).
Article Snippet: All markers were quantified by Enzyme-linked immunosorbent assays (ELISA) commercial kits: procollagen-I (ab210579, Abcam, Cambridge, UK), WISP-1 (Mouse/Rat WISP-1/CCN4 Quantikine ELISA Kit, MWSP10, Bio-Techne, Minneapolis, MN, USA), MMP7 (Rat MMP-7 ELISA Kit, NBP3-06896, Bio-Techne, Minneapolis, MN, USA), PDGF (Rat PDGF ELISA Kit, orb567597, Biorbyt Cambridge, UK), FGF2 (Mouse and Rat FGF basic/FGF2/bFGF ELISA Kit—Quantikine, MFB00, Bio-Techne, Minneapolis, MN, USA) and VEGF-A (Rat VEGF-A ELISA Kit, ab100787, Abcam, Cambridge, UK).
Techniques: Drug discovery, Clinical Proteomics, Control, Cream